Testosterone Cypionate Manufacturing, Supply & Shortage History

What Testosterone Cypionate Is and Why Manufacturing Complexity Matters

Testosterone cypionate is the 17-beta cyclopentylpropionate ester of testosterone, dissolved in cottonseed oil at concentrations of 100 mg/mL or 200 mg/mL for intramuscular or subcutaneous injection. The ester prolongs absorption from the depot, producing a half-life of roughly 8 days compared to under 2 hours for unesterified testosterone. That pharmacokinetic advantage made it the dominant injectable androgen in the United States for decades.

Regulatory Schedule and What It Means for Supply

Because testosterone is anabolic, the Controlled Substances Act places it in Schedule III. The Drug Enforcement Administration sets an annual aggregate production quota (APQ) for Schedule III anabolic steroids under 21 U.S.C. § 826. Manufacturers must apply each year for an individual manufacturing quota, and the DEA can adjust those figures based on estimated medical need, inventory levels, and diversion risk. This quota system creates a structural ceiling on how much raw API any single plant can process in a calendar year, even when market demand spikes unexpectedly. The FDA's Drug Shortages Staff tracks downstream effects and publishes current shortage status on its Drug Shortages Database.

The Active Pharmaceutical Ingredient Supply Chain

Testosterone API is synthesized from phytosterol precursors, primarily stigmasterol and sitosterol extracted from soybean oil processing waste. The conversion pathway runs through multiple chemical intermediates and requires specialized steroid chemistry equipment. A 2019 FDA analysis of sterile injectable drug shortages noted that API concentration in a small number of overseas manufacturers, combined with the controlled-substance quota layer, made androgen injectables particularly shortage-prone compared to non-scheduled generics. The FDA's report on drug shortage root causes identified manufacturing quality problems and single-source API dependency as the two most frequent drivers of injectable drug shortages.

How Testosterone Cypionate Works: Mechanism of Action

Androgen Receptor Binding and Genomic Signaling

After injection, the cypionate ester is hydrolyzed by esterases in muscle and plasma, releasing free testosterone. Free testosterone crosses cell membranes and binds the androgen receptor (AR) in the cytoplasm. The testosterone-AR complex translocates to the nucleus, dimerizes, and binds androgen response elements (AREs) to regulate transcription of hundreds of genes governing muscle protein synthesis, erythropoiesis, bone mineralization, and libido. A detailed review of AR signaling published in Endocrine Reviews describes this genomic pathway as the primary mediator of anabolic and androgenic effects.

Peripheral Conversion to DHT and Estradiol

Testosterone does not act exclusively as itself. In tissues expressing 5-alpha reductase (prostate, skin, hair follicles), testosterone is converted to dihydrotestosterone (DHT), which binds the AR with roughly 3-fold higher affinity. In adipose tissue, the aromatase enzyme (CYP19A1) converts testosterone to estradiol, which is necessary for bone density maintenance and cardiovascular health in men. The T-Trials investigators measured estradiol as a secondary endpoint and found that the sexual function benefit of testosterone treatment correlated as strongly with estradiol levels as with testosterone levels themselves, per the NEJM 2016 publication.

Non-Genomic Effects and Time Course

Testosterone also activates rapid, non-genomic signaling through membrane-associated androgen receptors and second-messenger cascades including PI3K/Akt. These effects appear within minutes rather than hours and may contribute to acute mood and energy changes some patients report within days of their first injection. The genomic effects, including measurable increases in lean mass and hemoglobin, take 6 to 12 weeks to become clinically apparent at standard therapeutic doses.

Clinical Evidence Supporting Use: The T-Trials

The Testosterone Trials (T-Trials) were a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 or older with a serum testosterone below 275 ng/dL and at least one symptom of hypogonadism. Published in the New England Journal of Medicine in 2016, the sexual function trial showed that testosterone gel (titrated to achieve serum levels of 500 ng/dL) increased the Psychosexual Daily Questionnaire score by 2.4 points versus 0.5 points for placebo (P<0.001). The physical function trial found a modest but statistically significant improvement in 6-minute walk distance. The bone trial, published separately, showed that testosterone increased volumetric bone mineral density at the spine by 7.5% versus 0.8% for placebo (P<0.001) per JAMA Internal Medicine 2017.

The T-Trials used a gel formulation, not testosterone cypionate, but the serum testosterone targets (400 to 700 ng/dL trough) are the same ones applied by the American Urological Association's 2018 guideline on testosterone deficiency and closely match practice recommendations from the Endocrine Society's 2018 clinical practice guideline for injectable testosterone esters.

Who Makes Testosterone Cypionate: Current U.S. Manufacturers

Brand and Generic Field

Pfizer manufactures the original brand-name product, Depo-Testosterone, at 100 mg/mL and 200 mg/mL in multi-dose vials. The FDA's Approved Drug Products database (Orange Book) lists multiple approved ANDAs for testosterone cypionate from Hikma Pharmaceuticals (formerly West-Ward), Perrigo, and Paddock Laboratories (now owned by Pfizer). The generic market is therefore not a true commodity market. Fewer than five distinct manufacturing sites supply the entire U.S. Demand, and each site must hold both FDA approval and an active DEA manufacturing quota.

Concentration Differences and Compounding

The 200 mg/mL multi-dose vial is the most commonly prescribed formulation for TRT because it limits injection volume. The 100 mg/mL vial is used for lower-dose protocols and subcutaneous injection, where smaller volumes are better tolerated. When commercial supply tightens, some prescribers turn to FDA-regulated 503B outsourcing facilities, which can compound testosterone cypionate under the Drug Quality and Security Act of 2013. The FDA maintains a list of registered 503B outsourcing facilities that have passed inspection. Patients and prescribers should verify current registration status before using any compounded product.

Documented Shortage History

2010 to 2013: Early Generic Consolidation Shortages

Testosterone cypionate appeared on the FDA Drug Shortages Database beginning around 2010, coinciding with a wave of generic manufacturer consolidations and plant remediation actions. During this period, Pfizer's Depo-Testosterone was intermittently the only reliably available product at some wholesalers, pushing acquisition costs upward and straining TRT programs at VA medical centers and public clinics. The FDA's drug shortage archive preserves records of these episodes, though historical entries are periodically archived and may require a FOIA request to retrieve fully.

2015 to 2016: DEA Quota Lag

In 2015 and 2016, a sharp rise in testosterone prescribing in the United States (driven in part by direct-to-consumer advertising and the expansion of men's health clinics) outpaced the DEA's quota allocations for that year. Manufacturers who had already consumed their annual API allotment could not legally produce additional product even with idle manufacturing capacity. The DEA's Automation of Reports and Consolidated Orders System (ARCOS) data, analyzed in a 2017 study in JAMA Internal Medicine, showed that testosterone prescriptions filled at retail pharmacies rose by 79% between 2010 and 2013 before plateauing, illustrating the demand shock that quota systems were slow to absorb.

2020 to 2021: COVID-19 Supply Chain Disruption

The COVID-19 pandemic disrupted steroid API production at overseas facilities and created logistics delays for the cottonseed oil excipient and stoppered glass vials used in sterile injectable manufacturing. The FDA's Drug Shortages Task Force 2020 report documented that sterile injectables were disproportionately affected because their supply chains involve multiple specialized inputs. Testosterone cypionate shortages during this period were moderate rather than severe in most regions, partly because telehealth expansion for TRT had not yet peaked, but pharmacists at several national chains reported allocation limits from wholesalers through much of 2021.

2022 to 2024: Telehealth TRT Demand and Current Status

The post-pandemic expansion of telehealth testosterone prescribing produced the most sustained demand pressure on the testosterone cypionate supply chain in the drug's history. The number of men receiving testosterone prescriptions through direct-to-consumer telehealth platforms grew substantially between 2021 and 2024. FDA shortage database entries from 2023 listed testosterone cypionate injection as in shortage at multiple points, with the 200 mg/mL multi-dose vial most affected. Some specialty pharmacies reported 4 to 6 week delays for new patient fills during peak shortage windows.

The HealthRX clinical team uses a three-tier contingency protocol during documented shortage periods: (1) transition eligible patients to testosterone enanthate 200 mg/mL, which shares nearly identical pharmacokinetics and has its own separate manufacturer roster; (2) evaluate subcutaneous microdosing with the 100 mg/mL vial, which is typically less constrained; (3) refer patients requiring continuity to a verified 503B outsourcing facility. This protocol reduces the rate of unintentional testosterone discontinuation, which carries documented risks including bone density loss over periods exceeding 12 months per data from the Osteoporosis International journal.

What Drives Testosterone Cypionate Shortages: Root Causes

DEA Quota Mechanics

The DEA sets individual manufacturing quotas based on prior-year sales, projected medical demand, and Schedule III diversion risk. Manufacturers submit requests by May 1 for the following year. If prescribing volume rises mid-year (as it did in 2015 and again in 2022), quota cannot legally be increased quickly. The lag between demand signal and quota adjustment has been as long as 12 to 18 months in documented cases. The DEA's quota regulation framework outlines this process, and comments submitted to the DEA by pharmacy associations in 2016 specifically cited testosterone as an example of quota lag causing patient harm.

Sterile Injectable Manufacturing Constraints

Testosterone cypionate is a sterile injectable, and sterile injectables have the highest manufacturing complexity of any oral or topical dosage form. They require validated cleanrooms, terminal sterilization or aseptic fill-finish processing, 100% container closure integrity testing, and multi-year stability programs before a new batch can ship. The FDA's guidance on sterile drug products produced by aseptic processing sets out these requirements in detail. A single failed sterility test can result in a batch recall and immediate supply disruption lasting weeks.

Cottonseed Oil Excipient Dependency

Testosterone cypionate is formulated in cottonseed oil, which requires its own agricultural supply chain and refining process. Cottonseed oil for pharmaceutical use must meet compendial standards for peroxide value, free fatty acid content, and heavy metals. Crop failures, trade disputes affecting cotton-producing regions, and refiner consolidation have each contributed to excipient tightening in past shortage episodes. USP General Chapter <401> specifies the quality standards that pharmaceutical-grade cottonseed oil must meet.

Concentration-Specific Demand Spikes

The 200 mg/mL concentration represents the majority of testosterone cypionate dispensed in the United States because it halves injection volume for a given dose. When overall demand rises, the 200 mg/mL vial bears the brunt. Manufacturers cannot rapidly rebalance production between concentrations because filling lines are often set up for one concentration at a time, and a changeover requires cleaning validation that takes days to weeks. This concentration-specific bottleneck explains why the 100 mg/mL vial is frequently available during periods when 200 mg/mL is constrained.

Pharmacokinetic Profile and Dosing Implications for Supply Planning

Understanding the pharmacokinetics of testosterone cypionate is directly relevant to shortage management because the 8-day half-life allows for dose-interval flexibility that shorter-acting androgens do not. A patient injecting 100 mg once weekly can safely extend to 10 to 12 days between injections for 2 to 3 cycles during a supply crunch with only modest trough reductions. The Endocrine Society's 2018 guideline recommends monitoring trough testosterone at least 3 months after any dose or interval change, with a target trough of 400 to 700 ng/dL for most hypogonadal men.

Subcutaneous injection has become more common in telehealth TRT protocols. A 2017 study in Sexual Medicine in 40 men comparing subcutaneous to intramuscular testosterone cypionate found that subcutaneous administration at 75 to 100 mg weekly produced stable serum testosterone levels within the physiologic range with similar tolerability. Subcutaneous protocols typically use the 100 mg/mL vial, which is often available when 200 mg/mL is not.

Monitoring Parameters and Safety Considerations

The Endocrine Society guideline specifies checking hematocrit at baseline, 3 months, and 12 months. Testosterone stimulates erythropoiesis through EPO-independent and EPO-dependent pathways; hematocrit above 54% requires dose reduction or temporary discontinuation to reduce thrombotic risk per the FDA labeling for testosterone cypionate. Prostate-specific antigen (PSA) should be checked at 3 and 12 months in men over 40. The T-Trials reported a statistically non-significant increase in cardiovascular events in the testosterone arm (23 events vs. 20 in placebo) over 12 months, with the authors noting the trial was not powered for cardiovascular endpoints per the NEJM 2016 paper.

A 2023 randomized trial in men with pre-existing or high risk of cardiovascular disease, TRAVERSE (N=5,204), found that testosterone replacement did not increase major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months (hazard ratio 0.96, 95% CI 0.83 to 1.12), providing reassurance for prescribers treating higher-risk patients.

What Prescribers and Patients Should Do During a Shortage

Therapeutic Substitution Options

Testosterone enanthate (200 mg/mL in sesame oil) has a pharmacokinetic profile nearly identical to testosterone cypionate, with a half-life of 4 to 5 days. The Endocrine Society guideline lists both as acceptable injectable formulations. A direct milligram-for-milligram dose substitution is appropriate for most patients, with a follow-up trough testosterone level checked at 6 weeks to confirm target range. Pharmacies that cannot source testosterone cypionate can often source enanthate from different distributors because the products are manufactured at different sites with separate quota allocations.

Compounded Testosterone Cypionate

503B outsourcing facilities operating under 21 U.S.C. § 503B can compound testosterone cypionate for patient-specific or non-patient-specific (office stock) use without a patient-specific prescription when a shortage is declared. Prescribers should confirm that the facility holds current FDA registration and has passed a recent inspection. The FDA posts inspection outcomes for registered facilities at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. Compounded products do not carry FDA approval for safety and efficacy but are manufactured under cGMP standards when sourced from a 503B facility.

Documentation and Prior Authorization

During shortage periods, insurance prior authorization processes may deny claims for testosterone enanthate on the basis that testosterone cypionate is "available." Prescribers can address this by documenting the shortage with reference to the FDA Drug Shortages Database entry and specifying medical necessity for the alternative. The American Urological Association's position on testosterone therapy access supports shortage-driven therapeutic substitution in clinical correspondence.